Complicity - Publications - Faculty & Research - Harvard Business School

Filter Results: (805)

Filter Results: (805)

Show Results For

← Page 12 of 805 Results →

August 2024 (Revised February 2025)
Case

Novo Nordisk Foundation

By: Debora L. Spar and Julia M. Comeau

In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details

Keywords: Pharmaceutical Companies; Diabetes; Obesity; Foundation; Non-profit Management; Profit; Corporate Governance; Business or Company Management; Corporate Social Responsibility and Impact; Expansion; Philanthropy and Charitable Giving; Nonprofit Organizations; Pharmaceutical Industry; Denmark; Europe

September 2017
Teaching Note

The Productivity Decline: Demographics, Robots, or Globalization?

By: Laura Alfaro and Hayley Pallan

In the early 21st century, there was a noticeable trend of declining productivity growth. Despite the persistent decline in productivity growth, a consensus on its explanation had not been reached. Some of the debate focused on the technicalities of productivity... View Details

Keywords: Performance Productivity; Measurement and Metrics; Technological Innovation; Economic Slowdown and Stagnation; Globalization; Business and Government Relations

Article

Should Business Have Human Rights Obligations?

By: Nien-he Hsieh

Businesses and their managers are increasingly called upon to take on human rights obligations. Focusing on the case of multinational enterprises (MNEs), the paper argues we have reason to reject assigning human rights obligations to business enterprises and their... View Details

Keywords: Human Rights; Ruggie Principles; Corporate Responsibility; Multinationals; Rights; Multinational Firms and Management; Corporate Social Responsibility and Impact

Find at Harvard

April 2017
Supplement

Imprimis (B)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details

Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States

May – June 2011
Article

Too Many Cooks Spoil the Broth: How High Status Individuals Decrease Group Effectiveness

By: Boris Groysberg, Jeffrey T. Polzer and Hillary Anger Elfenbein

Can groups become effective simply by assembling high status individual performers? Though an affirmative answer may seem straightforward on the surface, this answer becomes more complicated when group members benefit from collaborating on interdependent tasks.... View Details

Keywords: Groups and Teams; Equity; Theory; Human Resources; Integration; Body of Literature; Performance Effectiveness; Status and Position; Experience and Expertise

Find at Harvard

March 2003
Case

Insurer of Last Resort? The Federal Financial Response to September 11

By: David A. Moss and Sarah A. Brennan

Examines the federal financial response to September 11, 2001: the airline bailout, the victim compensation fund, emergency aid to New York and Washington, and terrorism reinsurance. Less than two weeks after the attacks, the government had committed almost $40 billion... View Details

Keywords: Business and Government Relations; Insurance; Risk Management; United States

December 2019
Supplement

The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)

By: Erik Snowberg, Trevor Fetter and Amy W. Schulman

This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details

Keywords: Opioids; Addiction; Business and Stakeholder Relations; Product Launch; Ethics; Society; Pharmaceutical Industry

November–December 2019
Article

Pivoting Isn't Enough? Managing Strategic Reorientation in New Ventures

By: Rory McDonald and Cheng Gao

New ventures often experience deviations from their plans that oblige them to reorient in pursuit of better fit between their evolving products and their target customers. Yet research is largely silent on how managers explain such changes and justify their ventures in... View Details

Keywords: Strategic Reorientation; Technology Entrepreneurship; Innovation; Product Development Processes; Organizational Adaptation; Qualitative Methods (General); Entrepreneurship; Information Technology; Organizational Change and Adaptation; Strategy; Innovation and Invention; Product Development; Communication Strategy

Find at Harvard

September 2017 (Revised August 2018)
Case

The Productivity Decline: Demographics, Robots, or Globalization?

By: Laura Alfaro, Hayley Pallan and Sarah Jeong

In the early 21st century, there was a noticeable trend of declining productivity growth. Despite the persistent decline in productivity growth, a consensus on its explanation had not been reached. Some of the debate focused on the technicalities of productivity... View Details

Keywords: Productivity; Performance Productivity; Measurement and Metrics; Technological Innovation; Economic Slowdown and Stagnation; Globalization; Business and Government Relations

March 2015 (Revised December 2016)
Case

Philips Healthcare Latin America

By: Sunil Gupta

On a beautiful sunny afternoon in October 2013, Daniel Mazon (GMP 15), decided to take some time out of his busy schedule of the General Management Program (GMP) at the Harvard Business School to reflect on his company's situation. Mazon was the Vice President and... View Details

Keywords: Healthcare; Latin America; Organizational Structure; Salesforce Management; Health Care and Treatment; Medical Devices and Supplies Industry; Health Industry; Latin America

April 2014 (Revised March 2018)
Case

Texas Children's Hospital: Congenital Heart Disease Care

By: Michael E. Porter, Justin M. Bachmann and Zachary C. Landman

In 2014, Dr. Charles D. Fraser Jr., Surgeon-in-Chief of Texas Children's Hospital in Houston, was contemplating the future direction of the congenital heart disease program. The nation's largest pediatric hospital, Texas Children's was ranked by U.S. News & World... View Details

Keywords: Health Care; Congenital Heart Disease; Integrated Practice Units; Health Care and Treatment; Outcome or Result; Measurement and Metrics; Performance Improvement; Health Industry; United States; Texas

February 2002 (Revised February 2002)
Case

Morgan Stanley Japan, 2002

By: Tarun Khanna and Louis P. DiLorenzo, Jr

Thierry Porte, president of Morgan Stanley Japan, had spent the brisk November day in Tokyo with Eric Best, Morgan Stanley's head of scenario planning, outlining the exercise that all of the managing directors in Japan would participate in shortly. Japan remained mired... View Details

Keywords: Planning; Economic Slowdown and Stagnation; Investment Banking; Multinational Firms and Management; Banking Industry; Financial Services Industry; Japan; United States

22 Feb 2018
News

Economists cannot avoid making value judgments

April 2017
Case

Imprimis (A)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in... View Details

Keywords: Strategy; Healthcare; Drug Compounding; Pharmaceuticals; Compounding; Drug Development; Decision-making; Mark Baum; Imprimis; Small Business; Decisions; Cost vs Benefits; Business Strategy; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; United States

September 2013 (Revised June 2017)
Supplement

IBM and the Reinvention of High School (B): Replicating & Scaling P-TECH and Partners

By: Rosabeth Moss Kanter and Ai-Ling Jamila Malone

IBM's Corporate Citizenship office created an innovation in public education through a business-school partnership for widespread replication and diffusion. In 2012, while P-TECH (Pathways in Technology Early College High School) was still in its first year operating,... View Details

Keywords: Social Enterprise; Partnerships; Innovation; Entrepreneurship; Organizational Change and Adaptation; Leadership; Partners and Partnerships; Social Entrepreneurship; Education; Business and Community Relations; Innovation and Invention; Growth Management; Chicago; Idaho

June 2008
Article

Current State of Fellowship Hiring: Is a Universal Match Necessary? Is It Possible?

By: Christopher D. Harner, Anil S. Ranawat, Muriel Niederle, Alvin E. Roth, Peter J. Stern, Shepard R. Hurwitz, William Levine, G. Paul DeRosa and Serena S. Hu

Currently, approximately ninety percent of the six hundred twenty graduating orthopaedic residents are planning on entering a post-graduate fellowship. Since January of 2005, two of the largest fellowship match programs, Sports Medicine and Spine Surgery, were... View Details

Keywords: Medical Specialties; Recruitment; Selection and Staffing; Employment; Market Timing; Marketplace Matching; Health Industry

Find at Harvard

February 2021
Case

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta

This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details

07 Jul 2010
First Look

First Look: July 7

PublicationsRaise Your Prices! Authors:Frank V. Cespedes, Elliot Ross, and Benson P. Shapiro Publication:The Wall Street Journal, May 24, 2010 An abstract is unavailable at this time. Integrated Reports Voluntary Filing Authors:Robert G. Eccles and Mervyn King... View Details

Keywords: Martha Lagace

February 2018 (Revised December 2019)
Case

The Tax Man: Taxes in Private Equity Real Estate

By: Nori Gerardo Lietz, Timothy J. Becker, Ricardo Andrade and Sayiddah F. McCree

In January 2018, Caelan Langan, an associate at KSW Partners LLC (“KSW”), was asked by Katherine Scott, the partner for whom he worked, to recommend a proposed structure to acquire a prominent office building in San Francisco for their most recent fund. Caelan was... View Details

Keywords: Real Estate; Alternative Investment Structures; Property; Acquisition; Private Equity; Investment; Management; Taxation; Policy

April 2017
Supplement

Imprimis (C)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details

Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States

←
12
13
…
40
41
→